Edgar Engleman

Edgar Engleman

Founder bei BOLT BIOTHERAPEUTICS, INC.

Vermögen: 2 Mio $ am 31.03.2024

78 Jahre
Health Technology
Consumer Services
Finance

Profil

Edgar Engleman, M.D.
is a founding member and Chief Scientific Advisor of Vivo Capital.
Dr. Engleman is a Professor of Pathology and Medicine at the Stanford University School of Medicine, where he established and oversees the Stanford Blood Center, directs his immunology research team, and co-directs the Tumor Immunology and Immunotherapy Research Programs at the Stanford Cancer Institute.
He is an inventor of multiple patented technologies, has authored more than 300 publications in medical and scientific journals, and trained more than 100 graduate and postgraduate students.
Dr. Engleman is the lead inventor of the technology underlying a cancer immunotherapy known as Provenge (Sipulucel-T), which was shown to extend the life of patients who suffer from metastatic prostate cancer.
Provenge is the first in the class of personalized immunotherapeutic agents to be FDA approved for the treatment of cancer.
He is also the lead inventor of the technology underlying the immunotherapies in development at Bolt Biotherapeutics.
Dr. Engleman is the founder or cofounder of a number of biotech companies including Cetus Immune (acquired by Novartis), Genelabs (acquired by GlaxoSmithKline), Dendreon (acquired by Sanpower), and Vivo portfolio companies Medeor, Bolt, and Tranquis.
He currently serves on the boards of Bolt (BOLT) and several private companies including Tranquis, Synapse and Ossium.
He previously served on the boards of REGENEXBIO (RGNX), Eiger (EIGR), Soleno (SLNO), Intermune (ITMN, acquired by Roche), Insmed (INSM), Prestwick (acquired by Biovail) and Semnur (acquired by Sorrento (SRNE).
He received his BA from Harvard College and earned his M.D.
from Columbia University School of Medicine.
In 2017, he received the CABS K Fong Prize in Life Sciences for his biomedical discoveries and contributions.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
12.06.2023 1 278 227 ( 3,35% ) 2 Mio $ 31.03.2024

Aktive Positionen von Edgar Engleman

UnternehmenPositionBeginn
BOLT BIOTHERAPEUTICS, INC. Founder 22.01.2015
Founder 01.01.1996
Director/Board Member -
Vivo Co-Invest (S) LP Director/Board Member -
Founder -
Director/Board Member -
Stanford University School of Medicine Corporate Officer/Principal 01.01.1990
Alle aktiven Positionen von Edgar Engleman

Ehemalige bekannte Positionen von Edgar Engleman

UnternehmenPositionEnde
SOLENO THERAPEUTICS, INC. Director/Board Member 31.12.2017
EIGER BIOPHARMACEUTICALS, INC. Director/Board Member 18.09.2017
░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
░░░░░░ ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
Sehen Sie sich die Erfahrung von Edgar Engleman im Detail an

Ausbildung von Edgar Engleman

Harvard University Undergraduate Degree
Columbia University College of Physicians & Surgeons Doctorate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Edgar Engleman im Detail an

Beziehungen

100 +

Beziehungen ersten Grades

29

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen5
INSMED INCORPORATED

Health Technology

SOLENO THERAPEUTICS, INC.

Health Technology

REGENXBIO INC.

Health Technology

BOLT BIOTHERAPEUTICS, INC.

Health Technology

EIGER BIOPHARMACEUTICALS, INC.

Health Technology

Private Unternehmen21

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Electronic Technology

Health Technology

Health Technology

Health Technology

Health Services

Cetus Immune

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Vivo Co-Invest (S) LP

Sehen Sie sich die Unternehmensverbindungen an
  1. Börse
  2. Insiders
  3. Edgar Engleman